CT120 / IASO BIO - LARVOL DELTA

IASO Biotheraputics Completes Enrollment of First Patient in CT120's Phase I/II Registrational Clinical Trial (PRNewswire) - "IASO Biotherapeutics...today announced that the company's in-house-developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy (CT120) has completed enrollment of the first patient in the phase I/II registrational clinical trial for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL)."

Trial status • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Oncology

CT120, a novel fully human anti-CD19 x anti-CD22 dual targeted chimeric antigen receptor T cell product for the treatment of B-NHL and B-ALL (AACR 2022) - "Collectively, CT120 is a potent and safe anti-CD19×anti-CD22 dual target CAR-T product for the treatment of B-NHL and B-ALL, and now it is in registered phase 1/2 clinical trial."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IFNG • IL2 • TNFA

IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA (PRNewswire) - "IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicine announced on Oct 26, 2021 that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation (ODD) to the company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL)."

Orphan drug • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Oncology

"#IASOBiotheraputics #CT120 Granted #OrphanDrug Designation by the U.S. #FDA https://t.co/ma4eyNvQco" (@1stOncology)

FDA event • Orphan drug

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2; N=125; Not yet recruiting; Sponsor: Nanjing IASO Biotherapeutics Co.,Ltd

Clinical • New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies (Businesswire) - “IASO Biotherapeutics…announced the completion of $108 million Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases…Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies. The company will also use the funds to develop a broader pipeline of universal allogeneic cell therapies and cell products for the treatment of solid tumors, expanding global strategic partnerships on core assets to further diversify the Company’s existing portfolio and platforms.”

Financing • Oncology

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials (Businesswire) - "IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for cancer, today announced the clearance from China’s National Medical Products Administration (NMPA) of two Initial New Drug (IND) applications for CT120, the company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)."

IND • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

IASO Biotherapeutics Application for Clinical Trials of the Second Indication of its Fully Human CD19/CD22 Dual-targeted CAR-T Drug Accepted by NMPA (Businesswire) - "IASO Biotherapeutics...announced...that its clinical trial application for the in-house developed CD19xCD22 fully human dual-targeted CAR T-cell therapy (CT120) for treatment of its second indication for relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL), has been accepted by the National Medical Products Administration (NMPA) (Acceptance No.: CXSL2101088, CXSL2101089). This acceptance came just one day after the acceptance of the drug’s first indication for treatment of CD19xCD22 positive relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)."

Non-US regulatory • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

IASO Receives NMPA Acceptance of its First Indication IND Application for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy (Businesswire) - “IASO Biotherapeutics…announced that its investigational new drug (IND) application for CT120, a fully human CD19/CD22 dual-targeting chimeric antigen receptor (CAR)-T cell therapy, has been approved by the China National Medical Products Administration (NMPA) (acceptance number CXSL2101070) for treatment of relapsed/refractory B-acute lymphoblastic leukemia (B-ALL).”

Non-US regulatory • Acute Lymphocytic Leukemia • Hematological Malignancies • Oncology